PCSK9 Inhibitors: New Class Of Cholesterol Drugs Shows Promise In Trials
In a 12-week trial of about 130 patients already on high doses statins, the Pfizer drug cut LDL cholesterol by 56 percent
pcsk inhibitor new class cholesterol dr USA show promise trials week trial patient high dose statin pfizer drug cut ldl cholesterol percent